The combination therapy will be evaluated as part of the U.S. National Institutes of Health's Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV)-2 trial in ambulatory COVID-19 patients. In the phase II study, safety and efficacy was established in a group of 220 ambulatory patients with COVID-19 who were at high risk for progression to severe disease.

The phase III study includes international trial sites, which will allow a broader assessment of the BRII-196 and BRII-198 combination in ambulatory COVID-19 patients. In addition, the company stated the trial may include data on how its candidate therapy performs against newly emerged SARS-CoV-2 variants.

Inovio will not conduct phase III COVID-19 vaccine trial in U.S.
Inovio announced it is planning for a phase III trial outside of the U.S. for its INO-4800 COVID-19 vaccine candidate after the U.S. Department of Defense...

Valneva begins phase III COVID-19 vaccine trial
Valneva announced it has initiated a phase III trial to evaluate its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001. The company's Cov-Compare...

EMA to review GSK, Vir COVID-19 mAb
GlaxoSmithKline (GSK) and Vir Biotechnology announced that the European Medicines Agency (EMA) has started a review of VIR-7831 (GSK4182136), an investigational...

Merck, Ridgeback to advance outpatient COVID-19 therapy to phase III trial
Merck and Ridgeback Biotherapeutics have announced they will move forward with a phase III trial of EIDD-2801/MK-4482 (molnupiravir), an oral antiviral...

NIH adds long-acting antibody COVID-19 therapy to ACTIV-3 master protocol
The National Institutes of Health (NIH) has begun a new arm of its master protocol, the Accelerating COVID-19 Therapeutic Interventions and Vaccines 3...